Abstract: OBJECTIVE To provide reference for pharmaceutical care of apatinib mesylate tablets induced renal glomerular damage in small cell lung cancer patients. METHODS The clinical data of a patient with renal glomerular damage after oral administration of apatinib was analyzed retrospectively. Combined with professional knowledge of clinical pharmacy, the causes of kidney damage and treatment measures was analyzed. Relevant literatures were reviewed, the kidney damage caused by oral administration of apatinib was proposed and the whole process of pharmaceutical care was implemented. RESULTS The renal glomerular damage induced by apatinib might be related to endothelial cell injury. The drug should be discontinued promptly for renal damage, and the dosage should be adjusted according to the degree of alleviation of adverse reactions. The kidney damage of the patient with clinical pharmacist's participation improved significantly. CONCLUSION Renal glomerular damage caused by apatinib is rare. Clinical pharmacists should strengthen the pharmaceutical care of patients using apatinib and adjust the medication plan in time to reduce the incidence of adverse reactions.